Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy
| Autor: | Chun-Chu Chang, Chien-Ying Liu, Hsiu-Fang Chen, Hsing-Wei Hung, Shu-Ching Chen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Lung Neoplasms Health Toxicology and Mutagenesis Taiwan cisplatin Antineoplastic Agents Gynecologic oncology chemotherapy Hospital Anxiety and Depression Scale Article 03 medical and health sciences 0302 clinical medicine Quality of life Internal medicine medicine Humans 030212 general & internal medicine Adverse effect Lung cancer Depression (differential diagnoses) Platinum business.industry Public Health Environmental and Occupational Health Peripheral Nervous System Diseases medicine.disease humanities lung cancer Cross-Sectional Studies quality of life Chemotherapy-induced peripheral neuropathy 030220 oncology & carcinogenesis carboplatin Medicine Anxiety Female medicine.symptom business chemotherapy-induced peripheral neuropathy |
| Zdroj: | International Journal of Environmental Research and Public Health Volume 18 Issue 11 International Journal of Environmental Research and Public Health, Vol 18, Iss 5677, p 5677 (2021) |
| ISSN: | 1660-4601 |
| DOI: | 10.3390/ijerph18115677 |
| Popis: | Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic anticancer drugs that may affect quality of life (QoL). Purpose: The purposes of this study were to: assess the levels of CIPN, anxiety, depression, CIPN–related QoL, and general QoL and identify the factors related to CIPN–related QoL and general QoL in patients with advanced lung cancer (LC) receiving platinum-based chemotherapy. This cross-sectional study examined patients with advanced LC who received platinum-based chemotherapy from the thoracic oncology inpatient wards of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ CIPN (European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy–induced peripheral neuropathy 20), anxiety (Hospital Anxiety and Depression Scale Depression Scale [HADS]), depression (HADS), CIPN-related QoL (Functional Assessment of Cancer Therapy /Gynecologic Oncology Group-Neurotoxicity subscale [FACT/GOG–Ntx]), and general QoL (Functional Assessment of Cancer Therapy–General Input [FACT-G]). Of 93 patients with advanced LC, 53.8% reported CIPN–sensory impairment and 47.3% reported CIPN–motor impairment. The most common CIPN symptoms were difficulty getting or maintaining an erection (only for men > 65 years) and difficulty in climbing stairs or getting up out of a chair. Poor CIPN–related QoL (FACT/GOG–Ntx) was associated with more CIPN–sensory and more CIPN–motor impairment. Poor general QoL (FACT-G) was associated with a higher level of depression, a higher level of anxiety, and receipt of more chemotherapy cycles. More than half of LC patients report impairment related to CIPN, calling for holistic treatment to improve QoL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|